RPG Life Sciences Reports FY26 Annual Results; Board Recommends Rs. 24 Dividend Per Share
RPG Life Sciences reported standalone revenue from operations of Rs. 70,752 lakhs and net profit of Rs. 11,517 lakhs for FY26, compared to Rs. 65,343 lakhs and Rs. 18,324 lakhs respectively in FY25. The Board recommended a final dividend of Rs. 24 per equity share (300% on face value of Rs. 8 each) for FY 2025-26, subject to shareholder approval. Exceptional items for FY26 included a net insurance claim recovery of Rs. 2,475 lakhs related to a fire incident at the API plant, an impact of Rs. 1,169 lakhs from the New Labour Codes, and an impairment of Rs. 916 lakhs on intangible assets under development. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years effective April 29, 2026, and the transfer of the API division to wholly owned subsidiary RPG Active Pharma Limited remains pending requisite approvals.
*this image is generated using AI for illustrative purposes only.
RPG Life Sciences Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at its meeting held on April 29, 2026, which commenced at 03:00 PM (IST) and concluded at 6:30 PM (IST). The statutory audit was conducted by S R B C & CO LLP, Chartered Accountants, who issued an unmodified opinion on both the standalone and consolidated financial statements.
Standalone Financial Performance
On a standalone basis, RPG Life Sciences delivered revenue from operations of Rs. 70,752 lakhs for the year ended March 31, 2026, compared to Rs. 65,343 lakhs in the previous year. Total income for the full year stood at Rs. 73,306 lakhs versus Rs. 66,611 lakhs in FY25. Total expenses for FY26 were Rs. 58,276 lakhs against Rs. 51,583 lakhs in FY25. The company's profit before exceptional items and tax remained broadly stable at Rs. 15,030 lakhs in FY26 compared to Rs. 15,028 lakhs in FY25. After accounting for exceptional items of Rs. 390 lakhs (net) in FY26 versus Rs. 8,260 lakhs in FY25, profit before tax stood at Rs. 15,420 lakhs compared to Rs. 23,288 lakhs in the prior year. Net profit for FY26 was Rs. 11,517 lakhs, against Rs. 18,324 lakhs in FY25.
The following table summarises the key standalone financial metrics:
| Metric: | Q4 FY26 (Audited) | Q3 FY26 (Unaudited) | Q4 FY25 (Audited) | FY26 (Audited) | FY25 (Audited) |
|---|---|---|---|---|---|
| Revenue from Operations (Rs. in Lakhs): | 17,689 | 18,003 | 14,309 | 70,752 | 65,343 |
| Other Income (Rs. in Lakhs): | 1,236 | 341 | 506 | 2,554 | 1,268 |
| Total Income (Rs. in Lakhs): | 18,925 | 18,344 | 14,815 | 73,306 | 66,611 |
| Total Expenses (Rs. in Lakhs): | 15,015 | 14,590 | 12,315 | 58,276 | 51,583 |
| Profit Before Exceptional Items & Tax (Rs. in Lakhs): | 3,910 | 3,754 | 2,500 | 15,030 | 15,028 |
| Exceptional Items (Net) (Rs. in Lakhs): | 110 | (842) | 10,990 | 390 | 8,260 |
| Profit Before Tax (Rs. in Lakhs): | 4,020 | 2,912 | 13,490 | 15,420 | 23,288 |
| Net Profit (Rs. in Lakhs): | 2,990 | 2,213 | 11,735 | 11,517 | 18,324 |
| Basic EPS (Rs.): | 18.08 | 13.38 | 70.96 | 69.64 | 110.80 |
| Diluted EPS (Rs.): | 18.08 | 13.38 | 70.96 | 69.64 | 110.80 |
Consolidated Financial Performance
On a consolidated basis, which includes subsidiary RPG Active Pharma Limited, the company reported revenue from operations of Rs. 70,752 lakhs and total income of Rs. 73,310 lakhs for FY26. Total consolidated expenses stood at Rs. 58,280 lakhs. Profit before exceptional items and tax was Rs. 15,030 lakhs, while profit before tax was Rs. 15,420 lakhs. Net profit for the consolidated entity was Rs. 11,517 lakhs for FY26, compared to Rs. 18,324 lakhs in FY25. Total comprehensive income for the period was Rs. 11,453 lakhs versus Rs. 18,214 lakhs in the prior year. Basic and diluted earnings per share (of Rs. 8/- each, not annualised for the quarter) stood at Rs. 69.64 for FY26 compared to Rs. 110.80 in FY25.
Exceptional Items
The exceptional items for FY26 reflect several non-recurring developments. The following table details the components:
| Exceptional Income / (Expenses) (Rs. in Lakhs): | Q4 FY26 (Audited) | Q3 FY26 (Unaudited) | Q4 FY25 (Audited) | FY26 (Audited) | FY25 (Audited) |
|---|---|---|---|---|---|
| Profit on assignment of surplus vacant leasehold land (MIDC, Navi Mumbai): | — | — | 12,623 | — | 9,893 |
| Net impact of Insurance claim (fire incident): | 1,087 | 266 | (1,633) | 2,475 | (1,633) |
| Impact of New Labour Codes: | (61) | (1,108) | — | (1,169) | — |
| Impairment of Intangible Assets Under Development: | (916) | — | — | (916) | — |
| Total Exceptional Items (Net): | 110 | (842) | 10,990 | 390 | 8,260 |
Regarding the fire incident at the company's API plant in Navi Mumbai, the insurance company acknowledged a claim amount of Rs. 3,137 lakhs as full and final settlement. The Group had recognised a cumulative loss of Rs. 2,295 lakhs up to December 31, 2025, and received Rs. 2,050 lakhs in multiple tranches up to that date. The balance of Rs. 1,087 lakhs was received in two tranches — Rs. 652 lakhs during Q4 FY26 and Rs. 435 lakhs in April 2026. Additionally, the Group received a final settlement of Rs. 791 lakhs towards compensation for loss of profit due to business interruption, recognised under Other Income for Q4 FY26. The impact of the New Labour Codes, notified by the Government of India on November 21, 2025, resulted in an incremental provision of Rs. 1,169 lakhs for FY26, primarily due to a change in wage definition. An impairment of intangible assets under development amounting to Rs. 916 lakhs was also charged off during Q4 FY26.
Dividend and Corporate Actions
The Board of Directors has recommended a final dividend of Rs. 24 (Rupees Twenty Four only) per equity share, representing 300% on the face value of Rs. 8 per share, for FY 2025-26. This is subject to approval of shareholders at the ensuing Annual General Meeting and will be paid or dispatched within 30 days of such approval.
The Board also approved the appointment of Dr. Pratit Samdani (DIN: 10139232) as an Additional Non-Executive Independent Director for a period of five years from April 29, 2026 to April 28, 2031, not liable to retire by rotation, subject to shareholder approval. Dr. Samdani is one of Mumbai's recognised physicians with over two decades of experience in Internal Medicine and Critical Care, and has contributed to research in Diabetes, Hypertension, Infectious Diseases, and Intensive Care Medicine. He holds a Gold Medal in F.C.P.S. (Medicine) and secured Second Rank in M.D. (Internal Medicine) from Bombay University, and has published in journals including the British Medical Journal (BMJ) and JAMA India. Dr. Samdani is not related to any Director or Key Managerial Personnel of the Company.
Balance Sheet and API Division Transfer
As at March 31, 2026, consolidated total assets stood at Rs. 79,316 lakhs compared to Rs. 65,781 lakhs as at March 31, 2025. Total equity was Rs. 60,535 lakhs versus Rs. 53,053 lakhs in the prior year. Cash and cash equivalents on a consolidated basis were Rs. 15,046 lakhs at year-end, up from Rs. 2,870 lakhs at the start of the year. The Board of Directors had approved, at its meeting held on December 15, 2025, the transfer of the API division of the Company to its wholly owned subsidiary, RPG Active Pharma Limited, which was incorporated on December 24, 2025, subject to receipt of all requisite consents and approvals. The company also amended its Code of fair disclosure, internal procedures and conduct for regulating, monitoring and reporting of trading by designated persons.
Historical Stock Returns for RPG Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.16% | +7.32% | +30.27% | +2.61% | +21.71% | +446.44% |
How will the transfer of RPG Life Sciences' API division to its wholly owned subsidiary RPG Active Pharma Limited impact the company's revenue mix, margins, and operational structure in FY27?
Given that core operating profit (before exceptional items) remained virtually flat at Rs. 15,030 lakhs despite an 8.3% revenue growth, what strategic initiatives is RPG Life Sciences pursuing to improve operating leverage and profitability in the coming years?
With cash and cash equivalents surging from Rs. 2,870 lakhs to Rs. 15,046 lakhs, how does RPG Life Sciences plan to deploy this capital — through acquisitions, R&D investment, capacity expansion, or further shareholder returns?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
